TULSA, Okla., July 21, 2005 (PRIMEZONE) -- Maxxon, Inc. (Pink Sheets:MXON) today announced the appointment of Andy Hu as the new Chief Technology Officer.
Hu is a medical products development specialist who came to the U.S., from Taiwan, in 1980. By 1982 he obtained his Masters degree in Engineering Management from University of Florida. It was natural for Hu to take advantage of his background and he began a career in establishing and investing in international manufacturing facilities. During his 15 years in the medical industry he has organized and managed an international team that includes sales people and engineers, in the USA, and a manufacturing team, in Taiwan and China.
Hu fully understands the huge culture and language gap between West and East, but believes in combining the strengths of West and East to create innovative products in a cost-effective approach. He has extensive experience in the U.S., China, Taiwan, and Japan, including years of interaction with major public medical device companies in these markets.
Hu has accumulated versatile, well-rounded knowledge and experience in creating and increasing the value of a company through global integration of Sales/Marketing, Manufacturing, Patents Acquisition & License, and Strategic Joint Venture Alliances.
"We are starting to build a dynamic management team. I am very pleased to have Andy on our side," stated Ronald Wheet, CEO of Maxxon.
"I am proud to be involved with an innovative company like Maxxon. Its ReVac Safety Syringe is an important step in combating needlestick injuries and protecting our healthcare workers from the risks of occupational exposure to HIV, Hepatitis B and C, and other blood borne pathogens," stated Andy Hu, CTO of Maxxon, who added, "Needlestick injuries can be reduced dramatically by retractable needles. The ReVac Safety Syringe features proprietary patented technology. By using a vacuum, rather then a costly spring, the product will have a distinct price advantage over spring load technology and should be very competitive with non-retractable syringes," stated Andy Hu, CTO of Maxxon.
About Maxxon
Maxxon is a development stage company committed to reducing the risk of accidental needlestick injuries and deaths to healthcare workers. Maxxon's 3cc. safety syringe, presently in development, is designed as a single-handed, vacuum-operated safety syringe that retracts the used needle into the syringe after use.
This press release contains some forward-looking statements. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect our business. Those uncertainties are discussed in Maxxon's SEC filings.